SCHEMBL1471745

SCHEMBL1471745

CC(=O)N[C@](C)(C(=O)O)c1cccc2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 2/20 0.45
HSD17B10 Q99714 1/20 0.45
ACP3 P15309 1/20 0.42
MTNR1A P48039 2/20 0.41
MTNR1B P49286 2/20 0.41
SSTR4 P31391 3/20 0.41
ABCC9 O60706 1/20 0.40
ABCC8 Q09428 1/20 0.40
KCNJ11 Q14654 1/20 0.40
KCNJ8 Q15842 1/20 0.40
CA12 O43570 1/20 0.40
CA4 P22748 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
PPARG P37231 2/20 0.40
PPARA Q07869 2/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27702983 1.00 KDM4E (0.45) KDM4EALDH1A1HSD17B10ACP3MTNR1A
SCHEMBL28546281 1.00 KDM4E (0.45) KDM4EALDH1A1HSD17B10ACP3MTNR1A
SCHEMBL3004207 0.85 ALDH1A1 (0.48) KDM4EALDH1A1HSD17B10ACP3SSTR4
SCHEMBL1748476 0.85 ALDH1A1 (0.48) KDM4EALDH1A1HSD17B10ACP3SSTR4
SCHEMBL6375660 0.85 ALDH1A1 (0.48) KDM4EALDH1A1HSD17B10ACP3SSTR4
SCHEMBL3390209 0.85 MAPT (0.43) KDM4EALDH1A1HSD17B10ACP3MTNR1A
SCHEMBL1878848 0.84 KDM4E (0.47) KDM4EALDH1A1HSD17B10ACP3SSTR4
SCHEMBL27507947 0.84 KDM4E (0.47) KDM4EALDH1A1HSD17B10ACP3SSTR4
SCHEMBL660493 0.84 KDM4E (0.47) KDM4EALDH1A1HSD17B10ACP3SSTR4
SCHEMBL27479791 0.80 KDM4E (0.44) KDM4EALDH1A1HSD17B10ACP3MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915224-B2 Method of preparing peptide AJINOMOTO CO., INC. (JP) 2011-03-29 US disclosed
EP-1584625-B1 Method of preparing tripeptide intermediates for the preparation of LHRH antagonists AJINOMOTO KK (JP) 2009-09-30 EP disclosed
US-20090234098-A1 METHOD OF PREPARING PEPTIDE AJINOMOTO CO., INC. (JP) 2009-09-17 US disclosed
US-7569548-B2 Method of preparing peptide AJINOMOTO CO., INC. (JP) 2009-08-04 US disclosed
EP-1584625-A1 Method of preparing tripeptide intermediates for the preparation of LHRH antagonists Ajinomoto Co., Inc. (JP) 2005-10-12 EP disclosed
US-20050203028-A1 Method of preparing peptide AJINOMOTO CO., INC. (JP) 2005-09-15 US disclosed
EP-1121446-A1 AMINOACYLASE AND ITS USE IN THE PRODUCTION OF D-AMINOACIDS Chirotech Technology Limited (GB) 2001-08-08 EP disclosed
WO-2000023598-A1 AMINOACYLASE AND ITS USE IN THE PRODUCTION OF D-AMINOACIDS CHIROTECH TECHNOLOGY LIMITED (GB) 2000-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234098-A1 METHOD OF PREPARING PEPTIDE GNRHR, VIP, LHCGR KDM4E 3942/4885ALDH1A1 4686/4885HSD17B10 1469/4885
US-20050203028-A1 Method of preparing peptide GNRHR, VIP, LHCGR KDM4E 3942/4885ALDH1A1 4686/4885HSD17B10 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.